IRIS
VESPASIANI GENTILUCCI, UMBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 10.496
NA - Nord America 3.564
EU - Europa 1.587
SA - Sud America 597
AF - Africa 83
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 2
Totale 16.355
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 7.486
US - Stati Uniti d'America 3.398
CN - Cina 1.242
HK - Hong Kong 811
IT - Italia 771
BR - Brasile 418
BD - Bangladesh 320
VN - Vietnam 271
GB - Regno Unito 211
FR - Francia 202
DE - Germania 127
IN - India 101
CA - Canada 76
AR - Argentina 64
MX - Messico 60
ID - Indonesia 46
FI - Finlandia 44
NL - Olanda 43
EC - Ecuador 34
TR - Turchia 34
UA - Ucraina 30
ZA - Sudafrica 29
CZ - Repubblica Ceca 28
PL - Polonia 27
AU - Australia 25
JP - Giappone 24
ES - Italia 20
PK - Pakistan 18
SA - Arabia Saudita 18
RU - Federazione Russa 17
CO - Colombia 16
IQ - Iraq 16
PH - Filippine 16
CL - Cile 15
PY - Paraguay 15
MY - Malesia 13
VE - Venezuela 13
PE - Perù 11
SE - Svezia 11
CH - Svizzera 9
EG - Egitto 9
UZ - Uzbekistan 9
JM - Giamaica 8
MA - Marocco 8
NP - Nepal 7
TN - Tunisia 7
TH - Thailandia 6
BO - Bolivia 5
ET - Etiopia 5
KE - Kenya 5
LB - Libano 5
NI - Nicaragua 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
BE - Belgio 4
BG - Bulgaria 4
BH - Bahrain 4
DZ - Algeria 4
HN - Honduras 4
IE - Irlanda 4
IL - Israele 4
OM - Oman 4
SY - Repubblica araba siriana 4
AO - Angola 3
AT - Austria 3
AZ - Azerbaigian 3
BY - Bielorussia 3
CY - Cipro 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
IR - Iran 3
KH - Cambogia 3
KR - Corea 3
KW - Kuwait 3
KZ - Kazakistan 3
LT - Lituania 3
LU - Lussemburgo 3
MD - Moldavia 3
RO - Romania 3
AL - Albania 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
CR - Costa Rica 2
IS - Islanda 2
JO - Giordania 2
ME - Montenegro 2
MN - Mongolia 2
PA - Panama 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TL - Timor Orientale 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
BJ - Benin 1
BW - Botswana 1
CI - Costa d'Avorio 1
DK - Danimarca 1
GH - Ghana 1
GN - Guinea 1
Totale 16.338
Salva come PNG Salva come JPEG
Città #
San Jose 1.105
Hong Kong 800
Singapore 798
Ashburn 715
Rome 536
Hefei 392
Beijing 296
Boardman 217
Dallas 184
Lauterbourg 172
London 158
Shanghai 138
Ho Chi Minh City 94
Los Angeles 85
Santa Clara 82
New York 70
Munich 62
Council Bluffs 60
Hanoi 51
San Francisco 48
São Paulo 48
Mexico City 44
Seattle 36
Brno 28
Pune 27
Toronto 27
Turku 27
Guangzhou 25
Amsterdam 24
Warsaw 23
West Jordan 22
Tokyo 21
Rio de Janeiro 20
Washington 19
Montreal 18
Helsinki 17
Buffalo 16
Chennai 16
Guayaquil 16
Milan 16
Boston 14
Naples 14
Orem 14
Da Nang 13
Haiphong 13
Canberra 12
Johannesburg 12
Charlotte 11
Frankfurt am Main 11
Manchester 11
Sona 11
Paris 10
Riyadh 10
Stockholm 10
Bologna 9
Brasília 9
Brooklyn 9
Chicago 9
Lahore 9
Las Vegas 9
Shenzhen 9
Curitiba 8
New Delhi 8
Phoenix 8
Quito 8
Atlanta 7
Denver 7
Hangzhou 7
Hải Dương 7
Kuala Lumpur 7
Melbourne 7
Tashkent 7
Zhengzhou 7
Bari 6
Biên Hòa 6
Buenos Aires 6
Kyiv 6
Lima 6
Mumbai 6
Pasadena 6
Redmond 6
Secaucus 6
Sydney 6
Thái Bình 6
Thái Nguyên 6
Belo Horizonte 5
Belém 5
Cairo 5
Campinas 5
Caracas 5
Florence 5
Houston 5
Istanbul 5
Jakarta 5
Kingston 5
Medellín 5
Nuremberg 5
Poplar 5
Ribeirão Preto 5
Shijiazhuang 5
Totale 7.017
Salva come PNG Salva come JPEG
Nome #
Altered metal metabolism in patients with HCV-related cirrhosis and hepatic encephalopathy 247
A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood' 246
A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation 240
Advances in management of periprosthetic joint infections: an historical prospective study 235
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection 230
Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations 230
Iloprost: an adjunctive approach to chronic viral hepatitis treatment 228
Anti-tumor necrosis factor-alpha reverts growth hormone resistance associated with inflammatory bowel disease 225
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study 225
METAL HOMEOSTASIS IN PATIENTS WITH PORTO-SYSTEMIC ENCEPHALOPATHY 224
Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study 224
Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients 222
Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 218
Retroperitoneal fibrosis and ankylosing spondylitis: which links? 214
Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C 214
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 214
Combined evaluation of aminotransferases improves risk stratification for overall and cause-specific mortality in older patients 214
Hepatic Lysosomal Acid Lipase and lipophagy in the progression of NAFLD 211
Factors enhancing treatment of hepatitis C virus⇓infected italian people who use drugs: The CLEO-GRECAS experience 211
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score 208
Granulomatous thyroiditis: an unexpected finding leading to the diagnosis of sarcoidosis 208
Impairment of GH/IGF-1 Axis in the liver of patients with hcv-related chronic hepatitis 205
BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES 203
Assessment of liver function by the exhaled breath-print during chronic liver disease 202
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 200
THU-390 - Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 172
Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography 169
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery 153
Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor 136
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination 135
Diabetes in chronic liver disease: from old concepts to new evidence 134
Drug–drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients 133
Exhaled breath analysis in hepatology: State-of-the-art and perspectives 132
[A 73-year-old woman with vomiting and metabolic alkalosis] 132
Growth hormone-stimulated insulin-like factor-1 and acid labile subunit in chronic liver disease 130
A challenging alfa-fetoprotein in a cirrhotic patient 129
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease 128
GH-resistance in different stages of chronic liver disease 127
[A 61-year-old woman with abdominal pain and urination disorders] 124
A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease 121
Association between non-invasive liver fibrosis scores and occurrence of health adverse outcomes in older people 119
METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY 118
Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age 114
[Ramipril and new therapeutic possibilities for ACE-inhibitors] 113
Portal diameter in the diagnosis of esophageal varices in 266 cirrhotic patients: which role? 112
Liver involvement in the course of thymoma-associated multiorgan autoimmunity: The first histological description 110
Diagnostic value of Virtual Touch Quantification (VTQ®) for differentiation of hemangiomas from malignant focal liver lesions 108
AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement 107
Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists 107
The PNPLA3 rs738409 variant can increase the risk of liver toxicity in multiple sclerosis patients treated with beta-interferon 106
Pain and Frailty in Hospitalized Older Adults 106
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores 106
Donna di 35 anni con febbre, dispnea e dolore alla coscia sinistra [A 35-year-old woman with fever, dyspnea, and pain in the left thigh]. 105
Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient 104
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study 103
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis 103
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 101
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis 98
LIVER TOXICITY IN COLORECTAL CANCER PATIENTS TREATED WITH FIRST LINE FOLFIRI-CONTAINING REGIMEN: A SINGLE INSTITUTION EXPERIENCE 96
Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass 95
Combining genetic variants to improve risk prediction for nafld and its progression to cirrhosis: a proof of concept study 89
An overview of deregulated lipid metabolism in nonalcoholic fatty liver disease with special focus on lysosomal acid lipase 88
Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study 88
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 82
Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures 76
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers 73
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience 73
IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids 72
Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease 70
Lipophagy Impairment Is Associated With Disease Progression in NAFLD 70
Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances 68
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen 67
Sarcopenia in Hepatocellular Carcinoma: Pathogenesis and Management 67
TNF-alpha and growth hormone resistance in patients with chronic liver disease 66
Reelin expression in human liver of patients with chronic hepatitis C infection 66
Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation 65
Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis 65
The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients 64
Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation 64
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD 63
Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice 63
Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank 63
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis 62
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen 62
Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population 61
Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables 61
Incidence and Outcome of Pneumomediastinum in Non-ICU Hospitalized COVID-19 Patients 61
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 59
Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development 58
Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease 58
Identification of matrix metalloprotease 10 (mmp10) as a key new mediator of the regenerative response of the liver 58
The Role of Ribavirin in the Combination Therapy of Hepatitis C Virus Infection 56
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease 56
Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology 56
Reply to the Letter: “Low levels of transaminase and mortality risk in older people with special reference to sarcopenia” 56
Identification of Fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure 55
Matrix metalloproteinase 10 contributes to hepatocarcinogenesis in a novel crosstalk with the stromal derived factor 1/C-X-C chemokine receptor 4 axis 55
Rare ATG7 genetic variants predispose patients to severe fatty liver disease 54
Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy 54
What changed in the Italian internal medicine and geriatric wards during the lockdown 54
Totale 12.282
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.876
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.876
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022336 0 2 8 0 3 3 2 6 46 4 4 258
2022/2023112 12 1 6 4 10 2 30 4 3 5 33 2
2023/2024636 26 50 18 62 61 269 2 37 8 40 20 43
2024/20258.381 131 57 236 45 110 186 143 34 482 562 3.017 3.378
2025/20266.968 620 332 457 810 255 354 1.755 409 534 665 432 345
Totale 16.433